Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies

BACKGROUND: The risk of SARS-CoV-2 infection and severity with disease modifying therapies (DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating increased risks of infection with B-cell-depleting (anti-CD20) therapies and severity, while others fail to observe an associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Tyler E, Madhavan, Maya, Gratch, Daniel, Patel, Aneek, Saha, Valerie, Sammarco, Carrie, Rimler, Zoe, Zuniga, Guadalupe, Gragui, Dunia, Charvet, Leigh, Cutter, Gary, Krupp, Lauren, Kister, Ilya, Ryerson, Lana Zhovtis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915504/
https://www.ncbi.nlm.nih.gov/pubmed/35398713
http://dx.doi.org/10.1016/j.msard.2022.103735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915504/
https://www.ncbi.nlm.nih.gov/pubmed/35398713
http://dx.doi.org/10.1016/j.msard.2022.103735

Ejemplares similares